Announcements Trials
Browse Landscape

Phase

Phase 2 158Phase 3 70Phase 1 43Phase 1/2 41Phase 2/3 8Phase 4 6Phase EARLY_PHASE1 4Phase NA 3

Status

Recruiting 4Completed 2

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 5Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1

Conditions

Waldenstrom Macroglobulinemia 1Neoplasms 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, B-Cell 1Heart Failure 1

Interventions

Dexamethasone 13Saline Solution 8Bupivacaine 8Bevacizumab 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Lenalidomide 7Fluorouracil 7pembrolizumab 6Rituximab 6Prednisone 6Letrozole 6Carboplatin 6Propofol 5Human Papillomavirus Recombinant Vaccine nonavalent 5trametinib 4lenvatinib 4dabrafenib 4cabozantinib 4anlotinib 4Trastuzumab 4Tamoxifen 4Standard of Care 4Sodium Chloride 4Ropivacaine 4Paclitaxel 4Immune Checkpoint Inhibitors 4Esomeprazole 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 4 × Rituximab × 1 year × Clear all
NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

AstraZeneca

Phase 4 Recruiting
60 enrolled
LymphoidOther hematologic neoplasm

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

NCT02844322 2026-02-11

BDH-WM01

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed
35 enrolled
Lymphoid

Waldenstrom Macroglobulinemia

NCT02858804 2026-02-11

BDH-MCL01

Institute of Hematology & Blood Diseases Hospital, China

Phase 4 Completed
55 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT07355699 2026-01-21

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

Beijing Tongren Hospital

Phase 4 Recruiting
88 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT07270835 2025-12-08

Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma

The First Affiliated Hospital of Soochow University

Phase 4 Recruiting
40 enrolled
LymphoidMyeloid

Lymphoma, B-Cell, Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡